Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3003893A
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
GSK3003893A is a small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) developed by GSK. RIPK1 is a critical signaling node that regulates inflammation and necroptosis, a regulated form of cell death. By blocking RIPK1 kinase activity, GSK3003893A is designed to suppress the release of pro-inflammatory cytokines and prevent tissue damage. The compound entered Phase 1 clinical trials for several inflammatory disorders, including psoriasis, rheumatoid arthritis, and ulcerative colitis. However, development for these indications appears to have been discontinued as the asset no longer appears in GSK's active clinical pipeline, with trials terminated for business reasons.
- Other names
- RIPK1 inhibitor GSK3003893RIPK-1 inhibitor GSK3003893RIPK 1 inhibitor GSK3003893
02
Targets
RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)
Beyond the preview
Go deeper on GSK3003893A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3003893A.